The practical mistake is treating GACP and EU-GMP as two grades of the same thing. They sit at different parts of the supply chain and must be evaluated against the product's actual stage and intended destination.
What GACP covers
The European Medicines Agency's current GACP guideline addresses growing, collecting and primary processing medicinal plants and herbal substances used for medicinal purposes. It is aimed at consistent quality in herbal starting materials and covers areas such as personnel, seeds and propagation material, cultivation, harvesting, primary processing, packaging, storage and documentation.
For procurement, a GACP claim should trigger questions about the exact legal entity and site, the basis for the claim, current document status, scope, crop or lot linkage, post-harvest steps and what downstream manufacturing remains. A certificate image without a current entity/scope match does not answer those questions.
What EU GMP covers
EU GMP guidance appears in EudraLex Volume 4. Its parts and annexes address manufacturing controls for medicinal products and active substances within the relevant legal and product framework. The correct GMP questions depend on the product stage and activities actually performed.
A statement that a partner or facility is “EU-GMP” should be tied to a named entity and site, the activities and product scope recorded in current public or controlled evidence, and the steps that entity will perform for this lot. A facility's status does not automatically attach to every product, activity, partner or future batch.
Side-by-side
Use each standard for the question it can answer.
| Decision area | GACP-oriented question | GMP-oriented question |
|---|---|---|
| Primary focus | How was the medicinal plant grown, collected and primarily processed? | How are relevant manufacturing operations controlled and documented? |
| Evidence unit | Entity/site, scope, document source and date, plus crop/lot records | Legal entity/site, authorized activity and product scope, current records and batch documentation |
| Lot decision | Does the lot trace to controlled cultivation and primary-processing records? | Which manufacturing/testing/certification steps have occurred, and which remain? |
| Commercial implication | Starting material may still require significant downstream work and cost | A GMP claim must still be checked against the exact stage, destination and release requirements |
| What it does not prove alone | Finished-product status, import permission, GMP manufacture, QP certification or destination acceptance | Current lot availability, commercial fit, import permission or acceptance by the buyer/authority |
The route handoff
The boundary between cultivation and manufacturing must be explicit.
The EMA GACP guideline discusses the interface with GMP and the need for written agreements where responsibilities are shared. For a commercial screen, map every step and owner rather than relying on a loose “GACP-to-GMP pathway” phrase.
Cultivation and harvest
Identify the producing entity/site, starting material, cultivation controls, harvest date and relevant records.
Primary processing and storage
Record drying, trimming or other primary processing, packaging, storage conditions, stability/shelf-life basis and traceability.
Manufacturing handoff
State where GMP-governed activities begin for the proposed route, the receiving entity and site, the activity scope and the transfer controls.
Testing, certification and release
Name the responsible parties, product/batch documentation, required testing and any QP certification or batch-release steps applicable to the intended destination.
Evidence test
Ask for scope, not just a logo.
Entity and site
Does the document name the same legal entity and facility that will handle the actual material?
Activity and product
Does the scope cover the relevant operation and product category, rather than a different activity at the same site?
Status and timing
Is the record current, and will the evidence still be valid when the proposed activity occurs?
Five common procurement errors
- Calling GACP “GMP lite.” The standards address different operational stages and questions.
- Equating a supplier with every downstream partner. A processor's or manufacturer's status is not the cultivator's status and does not prove a committed route.
- Comparing prices at different stages. Starting material at origin and finished material at destination carry different costs, risks and unknowns.
- Using representative evidence as lot evidence. A historic or sample COA may demonstrate capability but not the attributes of the offered lot.
- Treating future tense as completion. “Will be processed” or “can be released” remains a plan until the parties, scope, capacity, evidence and terms are established.
Buyer rule: define the required delivery stage first. Then test every proposed option against that same stage, route and commercial basis.
Primary sources
Read the current official material.
- EMA: Good agricultural and collection practice for starting materials of herbal origin — current effective version and superseded material.
- EMA: GACP Revision 1 PDF — adopted reference EMA/HMPC/246816/2005 Rev. 1.
- European Commission: EudraLex Volume 4 — current EU GMP guide and annexes.
- EudraGMDP — public authorization, certificate and non-compliance records.